CERO CERO THERAPEUTICS HOLDINGS, INC.: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $0 on the open market.
CERO revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$1.03M, EPS -0.70
- Quarter ended Mar 31, 2026: revenue n/a, net income −$5.89M, EPS -0.20
- Quarter ended Dec 31, 2025: revenue n/a, net income −$4.54M
- Quarter ended Sep 30, 2025: revenue n/a, net income −$4.86M, EPS -9.10
Recent CERO insider trades
- Dec 13, 2024: YK Bioventures Opportunities GP I, LLC sold 5,957,250 shares ($400K)
- Dec 10, 2024: YK Bioventures Opportunities GP I, LLC sold 3,658,364 shares ($383K)
5%+ owners
- Brian G. Atwood: 9.9% (Schedule 13D/A, filed Apr 4, 2025)